1. Home
  2. MNPR vs BLSM Comparison

MNPR vs BLSM Comparison

Compare MNPR & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$70.28

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Logo BlossomHill Therapeutics Inc. Common Stock

BLSM

BlossomHill Therapeutics Inc. Common Stock

N/A

Current Price

$14.77

Market Cap

483.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MNPR
BLSM
Founded
2014
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
587.4M
483.4M
IPO Year
2019
2026

Fundamental Metrics

Financial Performance
Metric
MNPR
BLSM
Price
$70.28
$14.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
5
Target Price
★ $130.17
$35.40
AVG Volume (30 Days)
127.0K
★ 168.2K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 54.99
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$50.07
$11.02
52 Week High
$124.82
$27.99

Technical Indicators

Market Signals
Indicator
MNPR
BLSM
Relative Strength Index (RSI) 42.77 46.56
Support Level $66.88 $12.93
Resistance Level $75.33 $17.53
Average True Range (ATR) 4.74 1.75
MACD 0.73 0.26
Stochastic Oscillator 51.81 56.94

Price Performance

Historical Comparison
MNPR
BLSM

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

About BLSM BlossomHill Therapeutics Inc. Common Stock

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Share on Social Networks: